摘要
目的:探讨在复方丹参针基础上加用依达拉奉治疗出血性脑梗死的临床效果和应用价值。方法:选取科室2010年12月-2012年12月之间120例出血性脑梗死患者,随机分为传统组和对照组,传统组患者在常规治疗基础上使用复方丹参注射液治疗;对照组患者在传统组基础上加用依达拉奉治疗,对比传统组和对照组的治疗结果。结果:传统组治疗之后,神经功能缺损程度评分为(15.38±5.39)分,对照组神经功能缺损程度评分为(9.78±4.69)分,对照组明显优于传统组,两者比较差异有统计学意义;传统组治愈27例(45.00%),显效13例(21.67%),有效7例(11.67%),治疗总有效率为78.33%;对照组治愈36例(60.00%),显效15例(25.00%),有效7例(11.67%),治疗总有效率达到了96.67%,对照组治疗临床效果明显优于传统组,两组结果对比差异有统计学意义。结论:在复方丹参注射液基础上联合使用依达拉奉可以更有效的治疗出血性脑梗死,且不良并发症少,安全性有保证,值得推广使用。
Objective: To explore the treatment of hemorrhagic cerebral infarction and the clinical effect and application value of compound salvia mihiorrhiza injection with edaravone on the basis.Method: Selected 2010 December to 2012 December department between 120 cases of hemorrhagic cerebral infarction patients, who were randomly divided into conventional group and control group, the traditional group with Compound Dansben injection treatment on the basis of conventional treatment; patients in the control group and treated with edaravone in traditional group basis, compared with the traditional group and control group, treatment outcome.Result: After the treatment, the traditional group of nerve function defect score ( 15.38± 5.39 ), control group of nerve function defect score ( 9.78± 4.69 ), the control group was obviously better than the traditional group, the difference was statistically significant; the traditional group 27 cases were cured ( 45% ), effective in 13 cases ( 21.67% ), effective in 7 cases ( 11.67% ), the total effective rate was 78.33%; the control group 36 cases were cured ( 60% ), effective in 15 cases ( 25% ), effective in 7 cases ( 11.67% ), the total effective rate reached 96.67%, controlled clinical effect of treatment group is better than the traditional group, the two groups have statistical significance comparing results differences.Conclusion: The combined use of edaravone in Compound Danshen injection can be based on more effective treatment of hemorrhagic cerebral infarction, and the adverse complications, safety assurance, is worthy to be popularized.
出处
《中国医学创新》
CAS
2013年第16期123-124,共2页
Medical Innovation of China
关键词
出血性脑梗死
复方丹参注射液
依达拉奉注射液
Hemorrhagic cerebral infarction
Compound Danshen injection
Edaravone injection